Amgen Expects At-Risk CERA Launch, But Says Swiss Gamble Won’t Pay Off

After failing to block the importation of pegylated erythropoietin, Amgen anticipates Roche will launch its continuous EPO receptor activator Mircera at risk

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet